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Background: Graying of hair–a sign of aging–raises cosmetic 
concerns. Individuals with gray hair often look older than 
others their age; therefore, some dye their hair for aesthetic 
purposes. However, hair colorants can induce many pro-
blems including skin irritation, allergic reaction and 
hair-breakage. Objective: This randomized, double- blind 
clinical trial was performed in order to examine the effects of 
APHG-1001, a compound including an extract from 
Pueraria lobata, on graying hair. Methods: A total of 44 
female subjects were randomly treated with either 
APHG-1001 or placebo twice daily for 24 weeks. Using the 
phototrichogram analysis, a count of newly developed gray 
hair was estimated. Investigator assessment and subject 
self-assessment were also performed in order to evaluate the 
efficacy of the compound. Results: The mean number of 
newly developed gray hair at 24 weeks was 6.3/cm2 in the 
APHG-1001 group and 11.4/cm2 in the placebo group; the 
difference was statistically significant (p＜0.05). However, 
the investigator assessment and subject self-assessment did 
not show any significant change in the gross appearance of 
hair grayness by the end of the study. No severe adverse 
events in either group were observed. Moreover, the 
incidence of adverse events did not differ between the 
groups. Conclusion: This clinical trial revealed that APHG- 
1001, which contains an extract of P. lobata, could prevent 
the development of new gray hair without any remarkable 
adverse effects. Thus, it can be considered as a viable 
treatment option for the prevention of gray hair. (Ann 
Dermatol 25(2) 218∼222, 2013)
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INTRODUCTION 
Graying hair is a distinct feature of aging1,2. It is known 
that gray hair often first appears during one’s thirties, and 
half of the people in their 50s have 50% gray hair3-5. In 
Korea, the prevalence of gray hair is 95.3% for people in 
their 50s6. Although gray hair does not cause any medical 
problems, it can make people appear older than their 
actual age7. Currently, with the extended human lifespan, 
the aged population is increasing. Hence, cosmetic 
demands for creating younger appearances are also 
increasing. Cosmetic concerns induced by gray hair are 
particularly prominent in Korean individuals, whose 
original hair color is very dark (close to black). Half of the 
Korean individuals over 50 years of age with gray hair dye 
their hair in order to cover the grayness8. However, hair 
colorants are composed of various chemicals and carry 
the risk of eliciting irritative and allergic contact reactions. 
For example, p-phenylenediamine–a major chemical com-
ponent of hair dye–is well known to induce contact 
dermatitis in its unpolymerized state9. 
 Prevention of Hair Graying by P. lobata Extract
Vol. 25, No. 2, 2013 219
Fig. 1. An example of counting new
gray hair developed during the 
treatment using the phototrichogram
analysis. Macro photographs of the
1 cm2 circular area were taken at 
baseline and at 24 weeks. We 
marked the pigmented hair with 
blue, existing gray hair with orange,
and new gray hair with purple. 
Pueraria lobata is a climbing, deciduous perennial vine, 
native to eastern Asia. Its extract reportedly include 
isoflavones puerarin, daidzein and genistein10, which have 
antioxidant properties11,12. In addition, we found that the 
extract from P. lobata promotes the expression of 
microphthalmia transcription factor (MITF) in vitro and 
prevents hair graying in MITFvit/mi mice (Park, 2012, 
unpublished data). Considering that MITF is a master 
transcriptional regulator of melanocytes, and that oxidative 
stress may be associated with hair graying13,14, the extract 
from P. lobata could potentially prevent graying of hair in 
humans. 
Currently, there are no medicines proven to prevent gray 
hair in humans. In this study, we performed a randomized, 
double-blind, placebo controlled study in order to examine 
the efficacy and safety of APHG-1001, a topical agent 




Healthy women (aged 35∼65 years) with gray hair were 
enrolled in this study. The exclusion criteria were as 
follows: significant systemic or chronic disease, hair loss 
greater than Ludwig type I, any hair or scalp disease, a 
history of any treatment for hair loss or hair graying within 
the previous 6 months, or a history of hair dyeing within 
the previous 1 month. The study protocols were approved 
by the Institutional Research Board of Seoul National 
University Hospital (H-0911-037-301) and written informed 
consent was obtained from all subjects. 
Investigational product (study agent)
APHG-1001 was provided by AMOREPACIFIC R&D 
Center and prepared as a colorless tonic spray containing 
1.0% P. lobata ethanolic extract, 0.5% Pleuropterus 
multiflorus extract and 0.5% ginkgo leaf extract. All plant 
extracts were kindly provided by Bioland Co. (Cheonan, 
Korea). A 50% ethanol solution was used as the vehicle. 
The placebo was also a colorless spray, without any active 
ingredients. 
Study design 
This was a randomized, double-blind, placebo-controlled 
study. A total of 44 subjects were randomly assigned to 
APHG-1001 or placebo for 24 weeks. They were instructed 
to use the spray twice daily, with 2 pumps (2 ml) for each 
dose. In order to remove any confounding effects of other 
topical agents, we provided standard shampoo to all study 
subjects and instructed them not to apply any other 
agents. The subjects returned to the clinic at 12 and 24 
weeks after their initial visit. 
Efficacy assessment 
The primary end point was the development of new gray 
hair during the course of the 24-weeks treatment, assessed 
by a phototrichogram analysis. Macro photographs of a 1 
cm2 circular area, 2 cm from the vertex, were taken at 0, 
12 and 24 weeks. At the first visit of each subject, the 
center of this scalp circle was marked with a small tattoo 
so that the same area could be photographed at each 
subsequent visit. At the conclusion of the study, we 
compared the macro photographs at 12 and 24 weeks 
with the baseline photograph and identified gray hair that 
had been dark-colored at the baseline (Fig. 1). New gray 
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 Values are presented as mean±standard deviation. *These data
were obtained from macrophotographs of a 1 cm2 circular area, 
2 cm from the vertex. 
Fig. 2. New gray hair developed after 12 and 24 weeks of 
treatment with APHG-1001 or with the vehicle. At week 24, 
there were fewer new gray hair in the APHG-1001 group than
in the placebo group. *p＜0.05, mean±standard error. 
hair developed during treatment were counted and 
statistically assessed between APHG-1001 and placebo 
groups. A camera system developed by Canfield Scientific 
Inc. (Fairfield, NJ, USA) was used in this study.
In order to perform investigator assessments, photographs 
of the temporal area were taken at baseline and at 24 
weeks. Hair on the temporal area of the scalp, 6 cm above 
the external auditory canal, was parted centrally with a 
comb. The separated strands of hair were fixed on either 
side of the parting with hair clips in order to photograph 
the area. Using a series of reference photographs showing 
increasing degrees of graying from 1 (all hair pigmented) 
to 10 (all hair white), a panel of 2 dermatologists 
independently scored the grayness by comparing the 
subject’s photographs at baseline and at 24 weeks with 
the reference photographs. The changes in score during 
the treatment were calculated for each subject and 
compared between groups.
The study subjects also performed a self-assessment. Each 
subject was requested to evaluate her own graying of hair 
using a visual analogue scale (VAS) from 0 (all hair 
pigmented) to 10 (all hair white) at baseline and at 24 
weeks of treatment.
Safety assessment
Safety of the treatment was assessed by the results from a 
physical examination and by the subjects’ self-reporting of 
adverse events. 
Statistical analysis
Subjects who completed all study schedules for 24 weeks 
were included in the study. The Paired t-test and 
chi-square test were used, respectively, for the change of 
efficacy variables during the study and the analysis of the 
incidence of adverse effects between groups. Analyses 
were performed using Statistical Package for the Social 
Sciences version 17.0 (SPSS Inc, Chicago, IL, USA). 
p-values of ＜0.05 were considered significant. 
RESULTS
A total of 44 subjects were recruited at screening. We 
randomly assigned 22 subjects to APHG-1001 and the 
other 22 subjects to placebo treatment. One subject was 
dropped out because of withdrawal of the consent; the 
remaining 43 subjects (21 in the APHG-1001 group and 
22 in the placebo group) were included for statistical 
analysis. 
Demographic characteristics
Subjects' demographics are summarized in Table 1. The 
mean age of the study participants was 48.9 years in the 
APHG-1001 group and 49.1 years in the placebo group. 
At baseline, the numerical counts of total hair and gray 
hair were measured at a 1 cm2 circular area of the scalp, 2 
cm from the vertex. There was no statistical difference 
between the two groups. 
Newly developed gray hairs
By comparing the macro photographs at 12 and 24 weeks 
with those taken at baseline, we identified newly 
developed gray hair in the 1 cm2 circular scalp area (Fig. 1). 
Although there was no difference in the number of new gray 
hair at 12 weeks, there were significantly fewer gray hair in 
the APHG-1001 group (6.3/cm2) than in the placebo group 
(11.4/cm2) at 24 weeks of treatment (p＜0.05) (Fig. 2). 
Investigator assessment and subject self-assessment 
The gross change in hair grayness during the 24-week- 
study was assessed by both study investigators (Fig. 3) as 
well as the subjects themselves. Two different investigators 
assessed the temporal scalp area and found that the 
grayness score changed slightly during the study period in 
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Fig. 3. Photographs of the temporal area in a subject treated with APHG-1001. Investigators did not find any visible change in gross 
hair grayness during the 24-week treatment. 
Table 2. Summary of adverse events







Values are presented as number (%). 
both groups; the mean change was ＋0.33 in the 
APHG-1001 group and ＋0.52 in the placebo group. The 
subjects were asked to self-assess their hair grayness using 
the VAS system at each visit; however, neither group 
showed any significant change; the mean change during 
the study was ＋0.52 in the APHG-1001 group and ＋
0.17 in the placebo group.
Safety assessment 
Although 3 of the 21 subjects in the APHG-1001 group 
and 3 of the 22 subjects in the placebo group complained 
of a certain discomfort with treatment, there were no 
systemic or serious adverse events (Table 2). The total 
number of reported complaints did not differ between the 
groups (p=0.95). Scalp irritation followed by coarse hair 
were the most common complaints. 
DISCUSSION
Graying of hair occurs when melanin is absent in the hair 
shaft. Melanins are synthesized in melanosomes, which 
are cytoplasmic organelles found in melanocytes, and the 
melanosomes are subsequently transferred to keratinocytes. 
In pigmented hair, the hair bulb melanocytes supply 
melanosomes to the keratinocytes located in the hair shaft. 
However, active hair bulb melanocytes are markedly 
reduced in gray hair15. Although the molecular mechanisms 
underlying the decreased number of melanocytes in the 
hair bulb are not yet fully elucidated, a ‘free radical theory 
of graying’ has been proposed14. Melanogenesis, a complex 
melanin-synthesizing pathway, generates high oxidative 
stress via the hydroxylation of tyrosine and the oxidation 
of DOPA and thus, melanocytes in the hair bulb may be 
particularly vulnerable due to their extraordinary melanogenic 
activity during the anagen phase of hair growth. This 
theory is supported by the accumulation of hydrogen 
peroxide in the hair shaft of human white scalp hair13. 
Theoretically, hair graying could be prevented if reactive 
oxygen species are adequately removed by effective 
antioxidants. 
The topical agent used in this study, APHG-1001, contains 
an extract of P. lobata as its major constituent. P. lobata, a 
kudzu-vine, is known to have antioxidant activity in vivo. 
In a diabetic rat model, oral administration of a quantified 
50% EtOH root extract of P. lobata for 3 weeks reduced 
the plasma level of malondialdehyde－a marker of 
oxidative damage to lipids16. The antioxidant activity of P. 
lobata is due to isoflavonoids, such as puerarin and 
daidzein. Puerarin, in particular, is reported to be correlated 
with the antioxidant activity of P. lobata12. In addition, our 
unpublished data indicate that the extract from P. lobata 
promotes the expression of MITF and melanogenesis in 
vitro, and its topical application prevents hair graying in 
MITFvit/mi mice (Park, 2012, unpublished data). 
In the present study, topical application of APHG-1001 for 
a period of 24 weeks prevented subjects from developing 
new gray hair growth. The number of new gray hair 
developed during the study was significantly smaller in 
the APHG-1001 group compared to the placebo group. 
However, the investigators’ assessment and subjects’ 
self-assessment did not reveal any marked change in hair 
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grayness during the 24-week treatment. There are several 
reasons that may account for this discrepancy. First, 
treatment response may differ according to different 
regions of the scalp. In this study, the macro photographs 
for the identification of new gray hair growth were taken 
near the vertex; however, the investigators’ assessment 
was performed at the temporal area. This discrepancy was 
inevitable because the vertex area, clipped for macro 
photographs, was not suitable for the investigators’ 
assessment. Second, the number of new gray hair was too 
small to produce a visible change in gross hair grayness. 
Because APHG-1001 cannot restore the original color of 
gray hair, the difference between the study groups 
indicates only the prevention of new gray hair. However, 
hair graying is a very slow aging process, usually taking 
more than 20 years for all scalp hair to become white 
from the first appearance of gray hair6; thus, only a few 
gray hair are expected to be developed during the course 
of 24 weeks under normal conditions. In order to identify 
the effect of APHG-1001 on the overall appearance of 
grayness, a study with a longer duration may be needed. 
In conclusion, a 24-week-treatment of the scalp with 
topical APHG-1001, a major constituent of which is P. 
lobata extract, prevented the development of gray hair. 
Moreover, no systemic or serious adverse events were 
observed. Therefore, topical APHG-1001 could be consi- 
dered as a treatment option for the prevention of gray hair.
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